

vTv Therapeutics Inc. Announces Pricing of Initial Public Offering

July 29, 2015

HIGH POINT, N.C.--(BUSINESS WIRE)--Jul. 29, 2015-- vTv Therapeutics Inc. (the "Company") (Nasdaq:VTVT) announced today the pricing of its initial public offering of 7,812,500 shares of its Class A common stock at a price to the public of \$15.00 per share. All of the shares are being offered by the Company. In addition, the Company has granted the underwriters an option to purchase up to an additional 1,171,875 shares of Class A common stock. The shares of Class A common stock are expected to begin trading on the Nasdaq Global Market on July 30, 2015, under the symbol "VTVT."

The Company intends to use the net proceeds of the offering to fund the STEADFAST Study (its ongoing Phase 3 trial of *azeliragon*, a drug candidate for the treatment of Alzheimer's disease), further clinical development of its other drug candidates (including two drug candidates for the treatment of type 2 diabetes that are in or commencing Phase 2 studies) and for working capital and other general corporate purposes.

Piper Jaffray & Co. and Stifel are acting as joint book-running managers for the offering. In addition, Canaccord Genuity Inc. and Janney Montgomery Scott LLC are acting as co-managers for the offering.

The offering is being made only by means of a prospectus. A copy of the final prospectus related to the offering may be obtained, when available, from Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone at (800) 747-3924, or by email at prospectus@pic.com; or Stifel, Nicolaus & Company, Incorporated, One Montgomery Street, Suite 3700, San Francisco, CA 94104, Attention: Syndicate, by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com.

A registration statement relating to these securities has been filed with, and declared effective by, the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About vTv Therapeutics

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. vTv has a pipeline of clinical drug candidates led by programs for the treatment of Alzheimer's disease and type 2 diabetes as well as treatment of inflammatory disorders and the prevention of muscle weakness.

Forward-Looking Statements

This press release contains forward-looking statements. You should not place undue reliance on those statements because they are subject to numerous uncertainties and factors relating to the Company's operations and business environment, all of which are difficult to predict and many of which are beyond the Company's control. Forward-looking statements include information concerning the Company's possible or assumed future results of operations, including descriptions of the Company's business strategy. These statements often include words such as "may," "will," "should," "believe," "expect," "anticipate," "intend," "plan," "estimate" or similar expressions. These statements are based on assumptions that the Company has made in light of its experience in the industry as well as its perceptions of historical trends, current conditions, expected future developments and other factors it believes are appropriate under the circumstances. Although the Company believes that these forward-looking statements are based on reasonable assumptions, we can give no assurance they will prove to be correct. Therefore, you should be aware that many factors could affect the Company's actual financial results or results of operations and could cause actual results to differ materially from those in the forward-looking statements. These factors are discussed in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections and elsewhere in the Company's registration statement.

You should keep in mind that any forward-looking statement made by the Company herein, or elsewhere, speaks only as of the date on which made. New risks and uncertainties come up from time to time, and it is impossible for the Company to predict these events or how they may affect it. The Company has no obligation to update any forward-looking statements after the date hereof, except as required by federal securities laws.



View source version on businesswire.com: <http://www.businesswire.com/news/home/20150729006885/en/>

Source: vTv Therapeutics Inc.

Investors

The Trout Group

Marc Panoff, 646-378-2958

mpanoff@troutgroup.com

or

Media

BMC Communications

Brad Miles, 646-513-3125

bmiles@bmccommunications.com